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Abstract 
Indeterminate dendritic cell tumor (IDCT) is an 
extremely rare hematopoietic malignancy. The 
indeterminate cells are considered a precursor stage 
of skin dendritic or Langerhans cells. IDCT is 
frequently misdiagnosed as another dendritic or 
histiocytic cell neoplasm, with Langerhans cell 
histiocytosis being the most common. Recently, 
cases with recurrent ETV3/NCOA2 translocation 
have been described. 
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Disease 
Indeterminate Dendritic Cell Tumor (IDCT) is an 
extremely rare hematopoietic malignancy (Horna P 
et al., 2017). The etiology of IDCT remains 
unknown.  An association between IDCT and others 
hematologic neoplasms has been reported (like B-
cell lymphomas, acute myeloid leukemia or chronic 
myelomonocytic leukemia (CMML)) (Rezk SA et 
al., 2008; Joo JW et al., 2018). Recently cases with 
recurrent ETV3/NCOA2 translocation have been 
described, being a potential therapeutic and 
diagnostic tool and proving that IDCT is a clonal 
entity (Brown RA et al., 2005). The indeterminate 
cells (IC) are considered a precursor stage of skin 
dendritic or Langerhans cells (Joo JW et al., 2018). 
IDCTs present with the same morphological, 
ultrastructural and immunophenotypic features than 
Langerhans cell histiocytosis (LCH) (Rezk SA et al., 
2008). Therefore LCH is one of the main disorders 
that should be excluded.  Features that help 
differentiate LCH from IDCT are the absence of 
Birbeck granules and the non-expression of langerin 
(CD 207) in IDCT cells (Ratzinger G et al., 2005). 
Neoplastic cells also express S100, CD1a, and 
CD68. IDCT mostly presents with skin involvement 
with one or more lesions like plaques, nodules or 
papules; but exceptionally affects lymph nodes or 
spleen (Dalia S et al., 2014). The clinical course is 
relatively benign; even so, it could vary from 
spontaneous regression (Ratzinger G et al., 2005) to 
stable disease or to progression and to recurrence 
(Joo JW et al., 2018). There is no standard treatment 
regimen and several approaches have been carried 
out. Given the good prognosis, aggressive systemic 
treatments are not usually performed (Joo JW et al., 
2018), and most lesions can be removed with surgery 
(Davick JJ et al., 2018). 
PATHOGENESIS It is not well described and 
remains unknown. ICs are considered pre-
Langerhans cells, which during migration towards 
epidermis are not able to incorporate Birbeck 
granules (Tan SK et al., 2017). Association with 
others neoplasms has been described and in some 
cases, a clonal relationship between IDCT and those 
tumors was present (Rezk SA et al., 2008). These 
findings, in CMML cases, could be explained by the 
capacity of malignant monocytes to differentiate into 
dendritic cells (Horna P et al., 2017). Despite the 
existence of clonal origin, morphologic and 
immunophenotypic characteristics are the same in 
isolated IDCTs (Horna P et al., 2017). Scabies mite 
infestations have also been postulated to play a role 
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on IDCT etiopathogenesis (Hashimoto K et al., 
2000). Demonstration of BRAF V600E mutation 
(O'Malley DP et al., 2015) and ETV3/NCOA2 gene 
fusion shed light on biology cell origin of IDCT, but 
further studies are needed to describe its implication. 
Epidemiology 
IDTC is a very uncommon disease; in fact, between 
1985 and 2016 only 85 cases were reported in the 
literature (Davick JJ et al., 2018). The median age at 
diagnosis is around 45 years, with a slight 
predominance in male gender (Davick JJ et al., 
2018). 
Clinics 
The vast majority of IDCT cases present cutaneous 
involvement (88%), whereas locations like lymph 
nodes (9%) and spleen (2.3%) are less common 
(Davick JJ et al., 2018). Plaques, nodules or papules 
are some of those skin lesions which often 
involucrate head, chest, trunk, back or extremities 
(Horna P et al., 2017). The tumor usually affects the 
dermis and, in some cases, the epidermis could also 
be compromised (Joo JW et al., 2018). Systemic 
symptoms, commons in others dendritic/histiocytic 
cell neoplasms, are infrequent in IDCT (Roh J et al., 
2016). It is important to highlight the indolent 
clinical course and the predilection for the skin in the 
cases of IDCT, in comparison with LCH, the main 
differential diagnosis disorder. 
Pathology 
IDCT and LCH share morphologic features, being 
difficult to distinguish between them. Dermal lesion 
presents a diffuse infiltration of oval mononuclear 
cells, with irregular nuclear grooves and abundant 
cytoplasm (Dalia S et al., 2014). The absence of 
eosinophilic infiltrates and epidermotropism 
(characteristic of LSC) supports the diagnosis of 
IDCT (Rezk SA et al., 2008; Horna P et al., 2017). 
Electron microscopy will strengthen our IDCT 
diagnosis showing the lack of Birbeck granules in 
the neoplastic cells (Rezk SA et al., 2008).  
IMMUNEPHENOTYPE Represents an essential 
diagnostic tool, that combined with electron 
microscopy, allow us to differentiate IDCT from 
LCH. Neoplastic cells characteristically express 
CD1a, S100, and variable CD68; being the key point 
(to exclude LCH) the negativity to langerin (CD207) 
(Tan SK et al., 2017). Also noteworthy is the non-
expression of markers of B/T, CD21, CD23 and 
CD35 cells (Dalia S et al., 2014).  
DIAGNOSIS IDCT is frequently misdiagnosed as 
another dendritic or histiocytic cell neoplasm, with 
LCH being the most common. Due to the similar 
histologic findings between these two entities, the 
clue lies in the lack of langerin (CD207) expression 
and Birbeck granules in IDCT. Therefore, 
phenotypic features and the electron microscopy 
study are the main pillars of IDCT diagnostic. 
Neoplastic cells present positivity for CD1a, S100 
and CD 68 (variable), and negativity for other 
dendritic/histiocytic, B and T cell markers. 
Morphologic findings that could also contribute to 
LCH exclusion is the absence of eosinophilic 
infiltration and epidermotropism. 
Cytogenetics 
The identification of ETV3/NCOA2 shows a new 
molecular landscape in IDCT, not described in other 
histiocytic neoplasms, which reaffirms that IDCT is 
a clonal disorder (Davick JJ et al., 2018). ETV3 
plays a role in last steps of macrophages 
differentiation as a transcription repressor in the cell 
cycle; whereas NCOA2 is involved in the activation 
of some nuclear hormone receptors as a transcription 
co-activator (Horna P et al., 2017). In addition, 
molecular alterations are also observed in those 
IDCT cases that were clonally related with other 
malignancies, such as trisomies of chromosomes 8 
and 21 or IGH/BCL2 translocations (Horna P et al., 
2017). 
Genes 
BRAF V600E mutations have been described 
similarly others histiocytic/dendritic cell neoplasms. 
Actually, these new molecular aberrations need 
thorough assessment to determine their impact on 
the tumor's biology and therapeutic approaches. 
Treatment 
There is no standardized treatment for IDCT, due to 
its rarity (Horna P et al., 2017). Surgical resection is 
usually the therapeutic choice in the majority of 
cases (Mo X et al., 2015; Dalia S et al., 2014). 
Psoralen and ultraviolet A therapy (PUVA) have 
been used with excellent responses, but not more 
than one year of follow-up does not allow an 
accurate assessment (Horna P et al., 2017). 
Chemotherapy treatments are reserved for 
disseminated cases, and still controversial (Dalia S 
et al., 2014). Aggressive therapies should be used 
with caution, since the slow benign clinical course of 
most of these tumors.  Spontaneous remission has 
also been reported.  
Clinical trials are recommended since they could 
determine optimal therapeutic approaches in the 
future. 
Prognosis 
IDCT is considered an indolent disorder in the vast 
majority of cases, presenting good responses to 
surgery (recurrence after resection is extremely 
rare).  Remission without treatment has also been 
reported. Prognostic factors are not been described 
usually IDCT (Joo JW et al., 2018). 
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